Skip to Main Content

Advertisement

Skip Nav Destination

Jeff P. Sharman, MD: Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL

December 30, 2021
On location

The novel anti-CD20 monoclonal antibody ublituximab (when added to ibrutinib) yielded superior response rates than ibrutinib alone in patients with high-risk chronic lymphocytic leukemia. Dr. Sharman discusses results of the phase III GENUINE study.

Advertisement

Connect with us:

CURRENT ISSUE
August 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement